Insmed (INSM) Non-Current Debt (2012 - 2026)
Insmed (INSM) posted Non-Current Debt of $546.8 million for Q2 2026, little changed on a QoQ basis from $546.8 million in Q1 2026, and little changed year-over-year from $546.8 million in Q2 2025.
Analysis
Insmed (INSM) Non-Current Debt (2012 - 2026) Analysis & Trends
Insmed has reported Non-Current Debt for 15 years, with the latest figure at $546.8 million in Q2 2026.
- On a quarterly basis, Non-Current Debt changed 0.0% year-over-year to $546.8 million in Q2 2026; TTM through Jun 2026 was $546.8 million, a 0.0% change from a year earlier, with the FY2025 full-year figure at $541.0 million, down 50.97% from the prior year.
- Non-Current Debt was $546.8 million for Q2 2026 at Insmed, roughly flat from $546.8 million in the prior quarter.
- The five-year high for Non-Current Debt was $1.2 billion in Q2 2024, with the low at $541.0 million in Q4 2025.
- Average Non-Current Debt over 5 years is $915.3 million, with a median of $1.0 billion recorded in 2024.
- The sharpest annual moves came in 2022 and 2025: Non-Current Debt soared 98.6% in 2022, then tumbled 54.06% in 2025.
- Over 5 years, Non-Current Debt stood at $1.1 billion in 2022, then grew by 2.67% to $1.2 billion in 2023, then declined by 4.49% to $1.1 billion in 2024, then sank by 50.97% to $541.0 million in 2025, then climbed by 1.07% to $546.8 million in 2026.
- The last three Non-Current Debt figures came in at $546.8 million (Q2 2026), $546.8 million (Q1 2026), and $541.0 million (Q4 2025), per Business Quant data.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Debt (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 236.37 Bn | 222.38 Bn | 7.24 Bn | 57.30 Bn |
| 2 | Gilead Sciences | 187.38 Bn | 184.12 Bn | 6.22 Bn | 26.25 Bn |
| 3 | Vertex Pharmaceuticals | 138.36 Bn | 130.51 Bn | 2.84 Bn | - |
| 4 | Regeneron Pharmaceuticals | 85.09 Bn | 77.10 Bn | 3.93 Bn | 1.99 Bn |
| 5 | Argenx Se | 63.93 Bn | 58.75 Bn | 1.37 Bn | - |
| 6 | Moderna | 58.07 Bn | 52.94 Bn | 52.00 Mn | 591.00 Mn |
| 7 | Alnylam Pharmaceuticals | 35.59 Bn | 32.28 Bn | 992.69 Mn | - |
| 8 | Biogen | 32.63 Bn | 31.34 Bn | 1.96 Bn | 7.29 Bn |
| 9 | Insmed | 27.57 Bn | 26.41 Bn | 358.27 Mn | 546.77 Mn |
| 10 | BioNTech SE | 26.24 Bn | 12.58 Bn | 10.00 Mn | 124.95 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 546.77 Mn |
| Mar 31, 2026 | 546.77 Mn |
| Dec 31, 2025 | 540.96 Mn |
| Sep 30, 2025 | 546.77 Mn |
| Jun 30, 2025 | 546.77 Mn |
| Mar 31, 2025 | 1.12 Bn |
| Dec 31, 2024 | 1.10 Bn |
| Sep 30, 2024 | 971.76 Mn |
| Jun 30, 2024 | 1.19 Bn |
| Mar 31, 2024 | 1.18 Bn |
| Dec 31, 2023 | 1.16 Bn |
| Sep 30, 2023 | 1.17 Bn |
| Jun 30, 2023 | 1.17 Bn |
| Mar 31, 2023 | 1.16 Bn |
| Dec 31, 2022 | 1.13 Bn |
| Sep 30, 2022 | 800.00 Mn |
| Jun 30, 2022 | 800.00 Mn |
| Mar 31, 2022 | 800.00 Mn |
| Dec 31, 2021 | 566.59 Mn |
| Sep 30, 2021 | 800.00 Mn |